Showing results (31-40 of 74) with videos related to

Sort By:
Pageof 8
Clinical Lymphoma, Myeloma & Leukemia|August 22, 2020
Phase 1 Trial Evaluating Vorinostat Plus Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple MyelomaJonathan L Kaufman, Roberto Mina, Jatin J Shah, et al.
Hemasphere|July 17, 2025
Current and future role of carfilzomib-based quadruplet combinations as therapy for newly diagnosed multiple myelomaOla Landgren, Noa Biran, Elizabeth K O'Donnell, et al.
Frontiers in Immunology|August 22, 2025
Pre-existing oncohematological disease in kidney transplant recipients: impact on graft survival, acute rejection, and long-term clinical outcomesAlberto Mella, Roberta Clari, Valeria Deiana, et al.
Haematologica|February 9, 2019
Once-weekly <i>versus</i> twice-weekly carfilzomib in patients with newly diagnosed multiple myeloma: a pooled analysis of two phase I/II studiesSara Bringhen, Roberto Mina, Maria Teresa Petrucci, et al.
Blood|August 20, 2013
Pomalidomide, cyclophosphamide, and prednisone for relapsed/refractory multiple myeloma: a multicenter phase 1/2 open-label studyAlessandra Larocca, Vittorio Montefusco, Sara Bringhen, et al.
Clinical Lymphoma, Myeloma & Leukemia|July 3, 2026
Clinical and Biological Implications of TP53 Abnormalities in Relapsed/Refractory Multiple Myeloma: The DEDALO StudyVittorio Montefusco, Anna Maria Cafro, Gloria Margiotta-Casaluci, et al.
Haematologica|February 29, 2020
Carfilzomib, cyclophosphamide and dexamethasone for newly diagnosed, high-risk myeloma patients not eligible for transplant: a pooled analysis of two studiesRoberto Mina, Francesca Bonello, Maria Teresa Petrucci, et al.
Hemasphere|January 12, 2026
Daratumumab-based quadruplet for patients with extramedullary multiple myeloma: Results from the Phase II prospective EMN19 studyMeral Beksac, Tulin Fıratlı Tuglular, Francesca Gay, et al.
Journal of Medical Economics|February 17, 2026
Indirect treatment comparison of DVRd plus DR maintenance (PERSEUS study) versus DVTd or VTd with or without lenalidomide maintenance in transplant-eligible patients with previously untreated multiple myelomaMeletios A Dimopoulos, Mario Boccadoro, Hermann Einsele, et al.
Hematological Oncology|June 2, 2024
A real-life study of daratumumab combinations in newly diagnosed patients with light chain (AL) amyloidosisClaudia Bellofiore, Pietro Benvenuti, Roberto Mina, et al.
Pageof 8